Narrative review offers theoretical basis for selecting biologic therapies in psoriasis patients with renal concerns

This narrative review focuses on the application of biologic agents, specifically TNF-alpha inhibitors, IL-17 inhibitors, and IL-12/23 inhibitors, for treating psoriasis in patients with renal concerns. The scope of the article is to synthesize existing knowledge regarding these medications within the context of kidney impairment. No specific sample size or study setting is reported for this synthesis.

The authors argue that these biologic agents represent a class of interventions that clinicians should consider for this patient group. The review does not provide pooled effect sizes or specific safety data regarding adverse events, serious adverse events, or discontinuations. Tolerability profiles are not detailed in the source text.

The primary limitation acknowledged is the lack of quantitative data, as the study phase and follow-up duration were not reported. The review does not establish causal links or provide specific p-values. Instead, it aims to guide theoretical decision-making rather than offering definitive clinical trial results.

The practice relevance is to give clinicians a theoretical basis for the rational selection of biologic therapies in psoriasis patients with renal concerns. Clinicians should interpret these findings as a framework for discussion rather than a guide based on hard numerical evidence.